Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA) (NCT00048542), a randomized phase 3 study. The primary outcome is Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase.

2. Clinical Question

This question is narrower than whether adalimumab was compared with placebo in all enrolled participants. The primary endpoint was specifically defined for the non-methotrexate stratum, and the randomized phase followed an open-label lead-in in which participants received adalimumab. The posted primary outcome therefore describes flare during the subsequent double-blind period among the eligible participants in that stratum. The trial also included a methotrexate stratum and other outcomes, but those are distinct from the primary question.

3. Trial Design

The registry describes a multicenter, Phase 3, randomized, quadruple-masked, parallel-group, placebo-controlled study. It enrolled 171 participants and is listed as completed. The study began in 2002-09, with primary completion in 2005-01. The sponsor is Abbott.

The study included children with polyarticular juvenile idiopathic arthritis who were either receiving methotrexate or not receiving it. The registry describes an open-label lead-in followed by a double-blind phase and open-label extension phases. During the lead-in, participants received adalimumab; the double-blind phase randomized adalimumab responders to adalimumab or placebo within their methotrexate stratum. In the non-methotrexate stratum, the primary analysis compared adalimumab with placebo without concomitant methotrexate. In the methotrexate stratum, the corresponding double-blind groups received their assigned treatment alongside methotrexate.

The primary outcome population was the intent-to-treat population as defined in the registry: randomized participants who received at least one administration of study drug, within the non-methotrexate stratum. The reported primary timeframe was Week 16 to Week 48, described as 32 weeks. The registry also lists open-label extension phases using body-surface-area and fixed-dose approaches. The original sample-size justification, planned interim analyses, detailed randomization procedure, and detailed allocation concealment procedures are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of 171 participants entered the Open-Label Lead-In (OL-LI) phase and received adalimumab. Of these 171 participants, 160 participants completed the OL-LI phase, and 133 participants entered the 32-week Double-Blind Phase (75 in the MTX stratum; 58 in the non-MTX stratum) and were randomized to adalimumab or placebo.

Only the first 6 of 8 groups are shown.

Double-Blind Phase

Reasons for not completing this period:

Open-Label Extension BSA Phase

Reasons for not completing this period:

Open-Label Extension Fixed Dose Phase

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All subjects in the intent-to-treat population, defined as all subjects who were randomized and who received at least a single administration of study drug, in the non-MTX stratum. Missing values were treated as disease flare.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase, measured over Week 16 to Week 48 (32 weeks).

The primary endpoint is the number of participants in the non-methotrexate stratum who had disease flare during the double-blind phase, from Week 16 to Week 48. The registry defines flare using changes in the six Juvenile Rheumatoid Arthritis core-set criteria: at least 30% worsening in at least three criteria, with a minimum of two active joints, and at least 30% improvement in no more than one criterion. Missing values were treated as disease flare for this endpoint.

This is a binary participant-level outcome: each participant either met the flare definition during the specified period or did not. Counting participants with the event gives an interpretable comparison of how often the prespecified flare criteria were met in each randomized group. It does not describe the timing or duration of each flare, the severity of a flare, or every change in disease activity. The registry lists time to onset of flare as a separate secondary outcome.

The endpoint is restricted to participants in the non-methotrexate stratum who entered the double-blind phase after responding to adalimumab during the lead-in. Its findings therefore speak to that study population and phase rather than to every child enrolled or to treatment-naïve comparisons across the entire trial.

7. Results Posted in the Registry

• Double-Blind Adalimumab: 43.3% (13/30) versus 71.4% (20/28) on control; risk difference -28.1 percentage points (95% CI -52.5 to -3.7), risk ratio 0.61 (0.38–0.97); unadjusted two-proportion z-test p = 0.031.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Number of Subjects Meeting Pediatric American College of Rheumatology 30% (PedACR30) Response Criteria at the End of the Open-Label Lead-In Phase

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Adalimumab: 74.4% (64/86) versus 94.1% (80/85) on control; risk difference -19.7 percentage points (95% CI -30.2 to -9.2), risk ratio 0.79 (0.69–0.90); unadjusted two-proportion z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for Adalimumab than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Number of Subjects in the MTX Stratum With Disease Flare During the Double-Blind Phase

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Double-Blind Adalimumab + MTX: 36.8% (14/38) versus 64.9% (24/37) on control; risk difference -28.0 percentage points (95% CI -49.7 to -6.3), risk ratio 0.57 (0.35–0.92); unadjusted two-proportion z-test p = 0.015.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for Double-Blind Adalimumab + MTX than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Number of Subjects Meeting PedACR30 Response Criteria at the End of the Double-Blind Phase

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Adalimumab: 56.7% (17/30) versus 32.1% (9/28) on control; risk difference 24.5 percentage points (95% CI -0.2 to 49.3), risk ratio 1.76 (0.95–3.29); unadjusted two-proportion z-test p = 0.061.
  • Adalimumab + MTX: 63.2% (24/38) versus 32.1% (9/28) on control; risk difference 31.0 percentage points (95% CI 7.9 to 54.1), risk ratio 1.96 (1.09–3.55); unadjusted two-proportion z-test p = 0.013.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Adalimumab and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically higher for Adalimumab + MTX than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The secondary outcomes cover several aspects of the study: PedACR30 response during the open-label lead-in, flare in the methotrexate stratum, PedACR response levels during the double-blind phase, time to flare, and physician assessment of disease activity. Collectively, the posted results give context beyond the primary non-methotrexate flare comparison. They do not all measure the same construct, use the same timeframe, or involve the same treatment groups.

The broad pattern is that some comparisons show differences between assigned groups while others are less conclusive by their reported tests and intervals. During the lead-in, both groups received adalimumab, so their response counts are descriptive of that phase and are not a randomized adalimumab-versus-placebo comparison. The double-blind methotrexate-stratum flare outcome provides a parallel comparison in a different treatment stratum. PedACR response outcomes are distinct from the primary flare endpoint and should be interpreted according to their own group definitions and timepoints.

These secondary results complement but do not replace the primary result. A response measure and a flare measure have different event definitions, and a finding for one should not be assumed to establish the same pattern for the other. In addition, the primary comparison is specifically among non-methotrexate participants who responded during the lead-in; secondary results may reflect other populations or phases.

The registry lists 22 outcome measures and 17 posted secondary outcomes. When many outcomes and comparisons are examined, some unadjusted p-values may fall below conventional thresholds by chance alone, even if there is no true effect for the corresponding comparisons. Unless a multiplicity strategy was prespecified and applied, secondary p-values carry less confirmatory weight than a single primary test. The multiplicity plan is not reported in the registry record. The secondary results are therefore best viewed as supporting context or as questions for further evaluation, rather than as independent definitive evidence.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Number of Subjects Meeting Pediatric American College of Rheumatology 30% (PedACR30) Response Criteria at the End of the Open-Label Lead-In Phase
• Number of Subjects in the MTX Stratum With Disease Flare During the Double-Blind Phase
• Time to Onset of Disease Flare During the Double-Blind Phase in Subjects in the Non-MTX Stratum
• Time to Onset of Disease Flare During the Double-Blind Phase in Subjects in the MTX Stratum
• Number of Subjects Meeting PedACR30 Response Criteria at the End of the Double-Blind Phase
• Number of Subjects Meeting PedACR50 Response Criteria at the End of the Double-Blind Phase
• Number of Subjects Meeting PedACR70 Response Criteria at the End of the Double-Blind Phase
• Mean Change From Baseline in Physician's Global Assessment of Disease Activity at Week 48 of the Double-Blind Phase

9. Statistical Interpretation

10. Statistical Methods Explained

For a binary endpoint, the basic descriptive result is the number of participants with the event and the number evaluated in each group. Here, those counts refer to participants meeting the disease-flare definition during the double-blind timeframe. This presentation keeps the numerator and group size visible, which helps distinguish an event count from a rate or from a count of repeated events.

What does the risk difference express?

The risk difference subtracts the event proportion in the comparator group from the event proportion in the intervention group. It is an absolute contrast: it describes the difference in the proportions experiencing the event, rather than how many times more or less likely the event was on a relative scale. A negative value in this comparison indicates a lower observed event proportion in the adalimumab group. The recalculated estimate is -0.281. This is an unadjusted comparison based on the posted group counts, not an adjusted model estimate.

Other common measures for binary outcomes include a risk ratio and an odds ratio. A risk ratio compares the event proportions as a ratio; an odds ratio compares the event odds. These measures use different scales and need not have the same numerical value. They are not interchangeable with the risk difference, and their interpretation depends on the outcome and comparison being studied. The registry’s sponsor analysis for the primary outcome is reported as a chi-square test, rather than as an adjusted effect estimate.

What does the chi-square test assess?

A chi-square test evaluates whether the observed distribution of events across groups is compatible with the null hypothesis of no association between assigned group and outcome, under the test’s assumptions. The registry reports a chi-square test with p = 0.031 for the primary comparison. The recalculated unadjusted p-value is also 0.031. A p-value is not the probability that the null hypothesis is true, and it does not describe the magnitude of the difference. Magnitude and uncertainty are better conveyed by the effect estimate and its confidence interval alongside the group counts.

How should the confidence interval be read?

A confidence interval gives a range of values produced by a procedure that, under its assumptions and repeated use, would cover the fixed underlying effect at the stated confidence level at the stated rate. For the primary recalculated risk difference, the interval is reported at 95% confidence and lies below zero. This is consistent with a lower observed event proportion in the adalimumab group, while the width of the interval shows that the estimate is not highly precise. The interval does not incorporate every possible source of uncertainty, such as differences between the trial population and other populations or limitations in outcome ascertainment.

Why does the endpoint definition matter?

The flare outcome is based on multiple disease-activity criteria and a joint-count condition, not on a single symptom or a direct count of all episodes. The registry also states that missing values were treated as flare for this primary outcome. That rule affects how missing outcome data contribute to the binary endpoint and should be considered when interpreting the counts. The analysis population is defined as randomized participants who received at least one study-drug administration, within the non-methotrexate stratum. Handling of missing data for other endpoints is not reported in the registry record.

Because this is a randomized, parallel-group comparison, the assigned groups are intended to support a between-group comparison within the stated stratum. Masking is listed as quadruple. The registry does not report enough detail to assess the implementation of randomization, concealment, or all analysis decisions. These unreported details should not be inferred from the design labels alone.

In general, over-dispersion is an issue when observed variability exceeds what a statistical model assumes; it can make model-based uncertainty estimates too small if ignored. The primary outcome is a binary event count, and the registry reports a chi-square test. Over-dispersion is not described as part of the registry’s primary analysis, so there is no basis in the record to claim that it was assessed or adjusted for.

11. Confidence Intervals and Precision

The recalculated primary risk difference is -0.281, and its reported 95% confidence interval lies below zero. Because both ends of the interval are on the same side of zero, the range of effects compatible with this calculation points in the direction of fewer recorded flares in the adalimumab group. The width of the interval nevertheless indicates uncertainty about the size of that absolute difference. The estimate should not be treated as an exact description of the underlying effect.

Precision depends in part on how much information the comparison contains. The primary groups include 30 participants assigned to adalimumab and 28 assigned to placebo. With group sizes of this scale, the observed proportions can be sensitive to the outcome of individual participants. A confidence interval makes some of that sampling uncertainty visible; the point estimate alone does not.

In general, a 95% confidence interval is generated by a procedure designed to cover the underlying effect in 95% of repeated samples when its assumptions hold. It is not a 95% probability statement about this specific interval or about a particular hypothesis. It also does not account automatically for unreported analytical choices, selection into the post-lead-in randomized comparison, or limitations in generalizing beyond the study participants.

The interval is for an unadjusted recalculation from the posted summary counts. The registry reports a chi-square test for the primary comparison, but does not report a sponsor confidence interval for the effect estimate. The interval and p-value are complementary summaries: the interval communicates both direction and uncertainty in the estimated difference, while the test p-value quantifies compatibility with a null model under the test assumptions.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning illustrations are stated as participants per arm for these binary outcomes. They use the observed effect as a reference and show alternative planning scenarios in which the effect to detect is 100%, 75%, or 50% of that observed effect. For example, planning for 100% of the observed primary effect gives 48 participants per arm for 80% power and 64 participants per arm for 90% power. Planning for 75% of the observed effect gives 84 participants per arm for 80% power and 111 participants per arm for 90% power. Planning for 50% of the observed effect gives 182 participants per arm for 80% power and 243 participants per arm for 90% power.

The stated calculation assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is the stated fraction of the observed effect. The trial’s original design assumptions and sample-size justification are not reported in the registry record; these illustrations do not describe the trial’s original planning.

In general, 80% power means that, under the calculation assumptions and for the specified effect, a study of that planned size would detect the effect at the chosen significance threshold in 80% of repeated studies. The 90% column expresses the same idea with a higher probability of detecting that specified effect, which requires a larger planned sample. Smaller effects need more participants to detect reliably than larger effects under the same assumptions. These figures are planning illustrations, not observed power.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.714; treatment proportion p₁ = 0.433; average p̄ = 0.574.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.6994 = 1.3707.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.6705 = 0.5643.
4. n = (1.3707 + 0.5643)² / (-0.2810)² = 47.4, rounded up to 48 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.714285714285714                          # control proportion
p1 <- 0.433333333333333                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(48542)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 48 (80% power), 64 (90% power)
 75% of observed effect: n per arm = 84 (80% power), 111 (90% power)
 50% of observed effect: n per arm = 182 (80% power), 243 (90% power)
power.prop.test: 47.4 
Simulated power at n = 48 per arm: 0.805 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

For the primary comparison, the registry reports a chi-square test with p = 0.031. The unadjusted recalculation from the posted group counts also gives p = 0.031. The recalculated risk difference is -0.281, with the interval estimate described in the precision discussion. The matching p-values indicate agreement at the displayed precision for this test result; they do not make the recalculated effect estimate a sponsor-reported adjusted estimate.

The registry’s primary analysis is the sponsor’s reported analysis for that endpoint. The recalculation is a simple unadjusted analysis of the posted summary counts and is useful as a transparent statistical cross-check. It cannot reproduce analytical details that are not in the registry record. No discrepancy is flagged for the primary result, and there is no basis in the record to replace the registry analysis with a different primary estimate.

For one secondary outcome, the registry reports a Pearson chi-square p-value that differs from the unadjusted recalculated p-value. The record does not explain that difference, so it should not be attributed to a particular statistical choice. Where the sponsor-reported result and a simple recalculation differ, they should be described as separate analyses rather than treated as interchangeable.

15. Multiplicity, Missing Data and Analysis Populations

The registry identifies a primary endpoint and lists multiple secondary outcomes, but the multiplicity procedure is not reported in the registry record. It is therefore unclear whether the study planned to control the overall chance of false-positive findings across the multiple secondary outcomes, comparisons, response thresholds, and treatment strata. This matters because interpreting each unadjusted p-value as if it were the only test can overstate the evidence when many tests are conducted.

The posted analyses include unadjusted recalculations and sponsor-reported tests. Unless a family-wise error or other multiplicity approach is documented, nominal p-values for secondary outcomes should be treated as exploratory evidence. The registry record does not report a hierarchy or gatekeeping procedure, nor does it describe how the analysis handled multiple endpoints. The original statistical analysis plan is not reported in the registry record.

For the primary endpoint, the registry defines the analysis population as randomized participants who received at least one administration of study drug in the non-methotrexate stratum. It also states that missing values were treated as disease flare. This is a specific missing-data rule for the primary outcome, and it places missing observations in the event category rather than excluding them from that endpoint’s classification.

Missing-data handling for the secondary outcomes is not reported in the registry record. The record does not specify whether those outcomes used the same missing-data rule, complete-case analysis, imputation, or another approach. It also does not provide enough detail to assess sensitivity analyses for missing outcomes. The primary rule is known, but the broader missing-data strategy should not be inferred from it.

The registry’s intent-to-treat definition is also narrower than a general label might suggest: it includes randomized participants who received at least one study-drug administration, within the relevant stratum. The record does not describe analyses of all randomized participants regardless of treatment receipt, per-protocol analyses, or sensitivity analyses using alternative analysis populations. These omissions limit assessment of how robust the conclusions are to analysis-population choices.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: arthritis (14.9%), juvenile arthritis (7.0%), adenoidal hypertrophy (3.5%), tonsillar hypertrophy (3.5%), urinary tract infection (3.3%).

The registry records serious adverse events and other adverse events separately for the double-blind groups and the open-label extension groups. In the double-blind non-methotrexate groups, serious adverse events affected 1 of 30 participants assigned to adalimumab and 0 of 28 assigned to placebo. In the methotrexate groups, serious adverse events affected 3 of 38 participants assigned to adalimumab plus methotrexate and 2 of 37 assigned to placebo plus methotrexate. The open-label extension groups also have serious adverse event counts, but those phases do not provide the same randomized placebo comparison.

These are counts of participants affected, not counts of all events, and they do not establish that study treatment caused an event. The registry lists several serious adverse event terms and percentages, including arthritis and juvenile arthritis, but the listed terms should be read as reported event categories, not as evidence of treatment causation. Open-label extension observations are descriptive and are subject to the limitations of a phase without the same blinded control comparison.

Death counts are not reported in the registry record. Event counts alone do not establish comparative safety, especially when the group sizes and phases differ. The safety information should be interpreted as a record of reported events during study follow-up, not as individualized risk guidance.

17. What the Result Does, and Does Not, Mean

The primary data show fewer participants meeting the registry’s disease-flare criteria in the adalimumab group than in the placebo group during the double-blind period in the non-methotrexate stratum. The unadjusted recalculated risk difference is -0.281, and the registry-reported chi-square p-value is 0.031. The result describes an observed contrast with statistical uncertainty; it does not by itself establish the size of any effect in other populations or settings.

The population is important to the meaning of the result. Participants had polyarticular juvenile idiopathic arthritis, were in the non-methotrexate stratum, and had responded to adalimumab during the open-label lead-in before the double-blind comparison. The primary finding does not directly answer what would happen among all children with the condition, among those who did not respond during the lead-in, or in a comparison that begins before exposure to adalimumab.

The endpoint also has a specific meaning. It records whether participants met a prespecified multi-criterion definition of flare during the stated timeframe. It is not a complete summary of each participant’s experience, and it does not measure every aspect of disease activity or treatment burden. Other secondary outcomes provide additional measures but are not interchangeable with the primary endpoint.

Statistical evidence and clinical importance are separate considerations. A p-value does not indicate the probability that a treatment effect is true, and a confidence interval does not eliminate uncertainty. The registry record does not provide a threshold for a clinically important difference, so the clinical importance of the observed contrast cannot be determined from these statistics alone.

The study’s results should not be interpreted as medical advice or as proof that treatment will or will not work for an individual. They are findings from a particular trial design, population, endpoint definition, and analysis. The registry does not report all details needed to evaluate every analysis choice, the multiplicity strategy, or the original sample-size rationale.

18. Why This Trial Matters Statistically

This trial illustrates why the details of population and study phase matter in interpreting a randomized comparison. Although the study enrolled children with polyarticular juvenile idiopathic arthritis, the primary endpoint concerns a narrower group: participants in the non-methotrexate stratum who had responded to adalimumab during an open-label lead-in and then entered the double-blind phase. The result is not a simple treatment-naïve comparison across everyone enrolled.

It also shows the value of distinguishing absolute effects, event counts, and hypothesis tests. The group counts make the underlying observed outcomes visible, the risk difference expresses the absolute contrast, and the chi-square p-value addresses compatibility with a null model. Reading those together gives a more complete account than relying on a p-value alone. The confidence interval adds information about precision and makes clear that an estimate remains uncertain even when a test result is comparatively small.

The trial further demonstrates why secondary outcomes require careful interpretation. Flare, response criteria, and physician assessment describe different outcomes, and the registry lists many measures. Without a reported multiplicity plan, individual unadjusted secondary results should not be treated as equally confirmatory. The distinction between blinded randomized phases and open-label extension observations also matters: the latter can describe events over follow-up but do not offer the same controlled contrast.

Finally, the record shows how explicit endpoint rules affect statistical interpretation. Treating missing primary endpoint values as disease flare is part of the outcome definition used in the analysis. Knowing that rule helps readers understand what the event counts represent, while the absence of corresponding details for other outcomes marks an important limit on evaluation.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary result applies to a selected study population. Participants in the non-methotrexate stratum entered the double-blind comparison after responding to adalimumab during the open-label lead-in. This limits direct application of the primary comparison to participants who were not lead-in responders or to a population beginning a randomized comparison without that lead-in exposure.

The primary endpoint is a defined binary flare outcome, and missing values were classified as flare. That rule is transparent in the registry, but the record does not report sensitivity analyses using alternative assumptions for missing outcomes. Handling of missing data for secondary outcomes is not reported in the registry record.

The posted primary comparison has modest group sizes, and the confidence interval is broad. The estimate therefore has appreciable uncertainty in its magnitude. The registry does not report a confidence interval from the sponsor’s analysis, detailed covariate adjustment, or enough methodological detail to assess all analysis decisions. It also does not report the original sample-size justification or the trial’s planned interim analyses.

Many outcome measures and secondary comparisons are listed, while a multiplicity strategy is not reported. This makes the confirmatory status of individual secondary findings difficult to assess. Some outcome measures relate to different phases and groups, including the open-label lead-in and extension, so their results should not be taken as equivalent to the randomized double-blind primary comparison.

The record describes serious adverse events in several phases, but event counts do not establish causation, and open-label extension groups lack the same controlled comparison as the double-blind phase. Death figures are not reported in the registry record. These limitations concern what can be inferred from the posted information and do not by themselves establish that the study was conducted improperly.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA) — NCT00048542.
• Registry record last updated 2011-08-22; status last verified 2011-08.
• Results first posted 2010-01-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

This completed Phase 3 study was multicenter, randomized, quadruple-masked, parallel-group, and placebo-controlled. It enrolled 171 children with polyarticular juvenile idiopathic arthritis who were either receiving methotrexate or not receiving it. The registry describes an open-label lead-in, a double-blind phase, and open-label extension phases.

The primary outcome was the number of participants with disease flare from Week 16 to Week 48 in the non-methotrexate stratum. The posted counts were 13 of 30 for adalimumab and 20 of 28 for placebo. The registry reports a chi-square p-value of 0.031; the unadjusted recalculation gives a risk difference of -0.281 and p = 0.031.

The interpretation is specific to the defined endpoint and the lead-in responder population. The registry does not report the original sample-size justification, multiplicity plan, or full missing-data strategy for secondary outcomes.